GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NuVasive Inc (NAS:NUVA) » Definitions » Cyclically Adjusted Revenue per Share

NuVasive (NuVasive) Cyclically Adjusted Revenue per Share : $23.01 (As of Jun. 2023)


View and export this data going back to 2004. Start your Free Trial

What is NuVasive Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

NuVasive's adjusted revenue per share for the three months ended in Jun. 2023 was $6.007. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $23.01 for the trailing ten years ended in Jun. 2023.

During the past 12 months, NuVasive's average Cyclically Adjusted Revenue Growth Rate was 7.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 12.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of NuVasive was 19.30% per year. The lowest was 12.40% per year. And the median was 15.80% per year.

As of today (2024-05-26), NuVasive's current stock price is $39.75. NuVasive's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 was $23.01. NuVasive's Cyclically Adjusted PS Ratio of today is 1.73.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of NuVasive was 4.54. The lowest was 2.52. And the median was 3.03.


NuVasive Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for NuVasive's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuVasive Cyclically Adjusted Revenue per Share Chart

NuVasive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.22 17.65 18.63 20.56 22.15

NuVasive Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.02 22.20 22.15 22.65 23.01

Competitive Comparison of NuVasive's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, NuVasive's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NuVasive's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NuVasive's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where NuVasive's Cyclically Adjusted PS Ratio falls into.



NuVasive Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NuVasive's adjusted Revenue per Share data for the three months ended in Jun. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=6.007/128.7287*128.7287
=6.007

Current CPI (Jun. 2023) = 128.7287.

NuVasive Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 3.582 98.790 4.668
201312 3.977 98.326 5.207
201403 3.876 99.695 5.005
201406 4.072 100.560 5.213
201409 4.042 100.428 5.181
201412 4.327 99.070 5.622
201503 3.720 99.621 4.807
201506 3.926 100.684 5.020
201509 3.770 100.392 4.834
201512 4.055 99.792 5.231
201603 4.335 100.470 5.554
201606 4.443 101.688 5.624
201609 4.296 101.861 5.429
201612 4.850 101.863 6.129
201703 4.309 102.862 5.393
201706 4.447 103.349 5.539
201709 4.680 104.136 5.785
201712 5.230 104.011 6.473
201803 5.086 105.290 6.218
201806 5.419 106.317 6.561
201809 5.101 106.507 6.165
201812 5.489 105.998 6.666
201903 5.236 107.251 6.285
201906 5.568 108.070 6.632
201909 5.482 108.329 6.514
201912 5.680 108.420 6.744
202003 4.837 108.902 5.718
202006 3.975 108.767 4.705
202009 5.700 109.815 6.682
202012 5.683 109.897 6.657
202103 5.279 111.754 6.081
202106 5.647 114.631 6.341
202109 5.242 115.734 5.831
202112 5.838 117.630 6.389
202203 4.646 121.301 4.930
202206 5.968 125.017 6.145
202209 5.671 125.227 5.830
202212 4.248 125.222 4.367
202303 5.890 127.348 5.954
202306 6.007 128.729 6.007

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


NuVasive  (NAS:NUVA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

NuVasive's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=39.75/23.01
=1.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of NuVasive was 4.54. The lowest was 2.52. And the median was 3.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


NuVasive Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of NuVasive's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


NuVasive (NuVasive) Business Description

Industry
Traded in Other Exchanges
N/A
Address
12101 Airport Way, Broomfield, CO, USA, 92121
NuVasive Inc is a medical technology company focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company has a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. It also develop and sell magnetically adjustable implant systems for spine and specialized orthopedic procedures.
Executives
Michael Farrington officer: SVP, People and Culture 7475 LUSK BLVD., SAN DIEGO CA 92121
Marc W. Rosenbaum officer: Chief Accounting Officer 7475 LUSK BLVD., SAN DIEGO CA 92121
James Christopher Barry director, officer: Chief Executive Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Andrew C. Morton officer: SVP, CHRO 10910 DOMAIN DRIVE, SUITE 300, AUSTIN TX 78758
Amy Belt Raimundo director ONE KAISER PLAZA, 22ND FLOOR, OAKLAND CA 94612
Lucas Vitale officer: Chief Human Resources Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Massimo Calafiore officer: EVP, Global Business Units 7475 LUSK BLVD., SAN DIEGO CA 92121
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Brent J. Boucher officer: EVP, Global Commercial 14 PLAZA DRIVE, LATHAM NY 12110
Matthew Link officer: Exec. VP U.S. Sales 7475 LUSK BLVD, SAN DIEGO CA 92121
Matthew K Harbaugh officer: EVP and CFO 675 MCDONNELL BLVD., HAZELWOOD MO 63042
Dale A. Wolf officer: SVP, Global Operations 7475 LUSK BLVD., SAN DIEGO CA 92121
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Mcclintock officer: President, U.S. Commercial 7475 LUSK BLVD, SAN DIEGO CA 92121